An Immunohistochemical study of Androgen Receptor and Beta-Catenin in Triple Negative Breast Cancers

Vani, K (2020) An Immunohistochemical study of Androgen Receptor and Beta-Catenin in Triple Negative Breast Cancers. Masters thesis, Madras Medical College, Chennai.


Download (4MB) | Preview


BACKGROUND: Breast cancer is the most common cancer worldwide and remains an important global health issue. Triple negative breast cancer accounts for 15% of breast cancers. The median survival of woman with advanced triple negative breast cancer is 13 months. Improved understanding is urgently required to advance our treatment approach to triple negative breast cancer. AIMS AND OBJECTIVES: 1. To evaluate the status of androgen receptor and beta-catenin in triple negative breast cancers. 2. To correlate the immunohistochhemical expression of these markers with histological grade. 3. To correlate the relation between androgen receptor and beta catenin. MATERIAL AND METHODS: This is a prospective and retrospective study of expression of androgen receptor and beta catenin in triple negative breast carcinomas conducted in the Institute of Pathology, Madras Medical College and Rajiv Gandhi Government General hospital, Chennai for a period of 2 years with 40 cases. The expressions are correlated with clinicopathological parameters. RESULTS: Androgen receptor evaluation in triple negative breast cancer which has a poor prognosis could help better understanding of these lesions and the possibility of specific targeted therapy. Beta catenin activity is required for many of the tumorigenic characteristics of triple negative breast cancer. Thus targeting beta catenin may have important implications in triple negative breast cancers therapy. CONCLUSION: In this study, the incidence of IBC-NOS type forms the highest among triple negative breast cancers. AR is expressed in 22.5% of cases and beta catenin 52.5% of cases. This study shows no statistically significant association between AR and beta catenin expression with histopathological parameters as the study sample is less and detection methods of these markers are yet to be validated. AR is significantly expressed in 22.5% of tumours which implicate the use of androgen related targeted therapy in these cases. AR could be an independent prognostic marker and additional AR related targeted therapies can be done if its methods of detections are validated and outcome is established. Beta catenin will have both prognostic and therapeutic significance if the signaling pathways are targeted and outcome established. Further studies are needed on the molecular characteristics of certain histologic types and it will improve our understanding of their prognostic implications and contribute to the tailored treatment.

Item Type: Thesis (Masters)
Additional Information: 201713009
Uncontrolled Keywords: Triple negative breast cancer, androgen receptor, beta catenin.
Subjects: MEDICAL > Pathology
Depositing User: Subramani R
Date Deposited: 29 Jan 2021 15:58
Last Modified: 29 Jan 2021 15:58

Actions (login required)

View Item View Item